Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
clinical trial data
Biotech
Merck, Daiichi repeat early success in small cell lung cancer
Merck and Daiichi reported an objective response rate of 54.8% in the 42 patients who received 12 mg/kg of I-DXd.
Nick Paul Taylor
Sep 9, 2024 10:27am
Relay breast cancer data tee up clash with AstraZeneca's Truqap
Sep 9, 2024 7:00am
Crestone’s antibiotic beats vancomycin at treating C. diff
Sep 5, 2024 3:11pm
Recursion's brain disease trial shows scant evidence of efficacy
Sep 3, 2024 10:30am
Arrowhead posts phase 3 data ahead of market clash with Ionis
Sep 3, 2024 9:27am
New data show how Bayer's asundexian failed to prevent strokes
Sep 1, 2024 3:40am